FindTrial
Sign In

Pimavanserin tartrate

DRUG5 trials

Sponsors

Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau, ACADIA Pharmaceuticals Inc., Tasly Pharmaceutical Group Co., Ltd

Conditions

Alzheimer's Disease PsychosisMajor depressive disorderParkinson's Disease Psychosis

Phase 2

A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
CompletedNCT02035553
ACADIA Pharmaceuticals Inc.Alzheimer's Disease Psychosis
Start: 2013-11-30End: 2016-10-27Updated: 2017-10-25
Antidepressant effects of psilocybin in the absence of serotoninergic psychedelic experience: a dimensional functional neuroimaging approach
Not yet recruitingCTIS2025-521690-14-00
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant PauMajor depressive disorder
Target: 60Updated: 2026-05-04

Phase 3

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
CompletedNCT01174004
ACADIA Pharmaceuticals Inc.Parkinson's Disease Psychosis
Start: 2010-07-31End: 2012-11-30Updated: 2014-03-26
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
CompletedNCT06068465
Tasly Pharmaceutical Group Co., LtdParkinson's Disease Psychosis
Start: 2024-09-27End: 2026-02-01Updated: 2026-02-27

Unknown Phase

Expanded Access of Pimavanserin for Patients With PD Psychosis
NCT02762591
ACADIA Pharmaceuticals Inc.Parkinson's Disease Psychosis
Updated: 2017-04-18

Related Papers

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis
Frontiers in Neurology2022-10-0513 citations
Pimavanserin: A Novel Antipsychotic With Potentials to Address an Unmet Need of Older Adults With Dementia-Related Psychosis.
2020-02-2620 citations
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
2018-03-01126 citations
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
2013-11-01461 citations